Projeto 3 Cuidados Básicos a ter com a pele
5. Conclusão
Considero que a realização deste tipo de atividades nas farmácias comunitárias portuguesas é de importância vital, não só na promoção de saúde dos utentes, como para permitir a aproximação destes à farmácia, ganhando cada vez mais confiança pelos profissionais que os acompanham e tornando-a como local prioritário para aconselhamento de determinadas patologias e problemas de saúde.
Bibliografia
1. Pordata, Principais Causa de Morte em Portugal, disponível: http://www.pordata.pt/ [acedido a 12/07/2016].
2. Ordem dos Farmacêuticos - A profissão em números, disponível: http://www.ordemfarmaceuticos.pt/ [acedido a 22/06/2016].
3. Ordem dos Farmacêuticos, Boas Práticas Farmacêuticas para a farmácia comunitária. 2009.
4. INFARMED ‐ Gabinete Jurídico e Contencioso. Aprova as boas práticas a observar na preparação de medicamentos manipulados em farmácia de oficina e hospitalar. Portaria nº 594/2004, de 2 de junho.
5. INFARMED ‐ Gabinete Jurídico e Contencioso. Aprova a lista de equipamento mínimo de existência obrigatória para as operações de preparação, acondicionamento e controlo de medicamentos manipulados, que consta do anexo à presente deliberação e dela faz parte integrante. Deliberação n.o 1500/2004, 7 de dezembro.
6. Decreto-Lei N.º 307/2007, de 31 de agosto – Regime Jurídico das Farmácias de Oficina. 7. Ministério da Saúde, Normas Relativas à Dispensa de Medicamentos e Produtos de
Saúde; 2015.
8. ANF, Insolvência ou penhora atinge uma em cada cinco farmácias (agosto 2016), disponível em: http://www.anf.pt/noticias/ [acedido a 23/07/2016].
9. Lei nº 11/2012, de 8 de março - Normas Relativas à Dispensa de Medicamentos e Produtos de Saúde.
10. AllianceHealthCare, ClientePlatina+, disponível em: http://www.alliance-healthcare.pt/ [acedido a 23/07/2016].
11. Decreto-Lei N.º 176/2006, de 30 de agosto – Estatuto do Medicamento.
12. Portaria nº 224/2015, de 27 de julho - Estabelece o regime jurídico a que obedecem as regras de prescrição e dispensa de medicamentos e produtos de saúde e define as obrigações de informação a prestar aos utentes.
13. INFARMED (2014). Normas Relativas à Dispensa de Medicamentos e Produtos de Saúde.
14. Portaria nº 224/2015, de 27 de julho - Estabelece o regime jurídico a que obedecem as regras de prescrição e dispensa de medicamentos e produtos de saúde e define as obrigações de informação a prestar aos utentes.
16. Decreto-Lei n.º 15/93, de 22 de janeiro - Regime jurídico do tráfico e consumo de estupefacientes e psicotrópicos.
17. Decreto-Lei n.º 106-A/2010, de 1 de outubro - Adota medidas mais justas no acesso aos medicamentos, combate à fraude e ao abuso na comparticipação de medicamentos e de racionalização da política do medicamento no âmbito do Serviço Nacional de Saúde. 18. Decreto-Lei n.º 48-A/2010, de 13 de maio - Regime Geral das comparticipações do
estado no preço dos medicamentos. 19. Portaria n.º 195-D/2015, de 30 de junho.
20. Portaria n.º 924-A/2010, de 17 de setembro - Define os grupos e subgrupos farmacoterapêuticos que integram os diferentes escalões de comparticipação do Estado no preço dos medicamentos.
21. Portaria n.º 924-A/2010, de 17 de setembro - Define os grupos e subgrupos farmacoterapêuticos que integram os diferentes escalões de comparticipação do Estado no preço dos medicamentos.
22. Ministério da Saúde - Legislação - Medicamentos, Comparticipação e Farmácias, acessível em http://www.sg.min-saude.pt. [acedido a 22 de junho de 2016].
23. Decreto-Lei n.º 242-B/2006, de 29 de dezembro - Estabelece o sistema de pagamento, às farmácias, da comparticipação do Estado no preço dos medicamentos.
24. Portaria N.º 1100/2000, de 17 de novembro – Critérios Técnico-Científicos para a alteração da classificação quanto à dispensa ao público.
25. Hernández, D.S., M.M.S. Castro, and M.J.F. Dáder, Método DADER: Manual de seguimento farmacoterapêutico. 1ª ed. 2010, Lisboa: Edições Universitárias Lusófonas. 26. Sociedade Portuguesa de Cuidados Farmacêuticos (2007). Estatutos da Sociedade
Portuguesa de Cuidados Farmacêuticos.
27. INFARMED: Resumo das Caraterísticas do Medicamento - Paracetamol generis 1000 mg. Aprovado em 08-05-2014.
28. INFARMED: Resumo das Caraterísticas do Medicamento - Dafalgan 1 g. Aprovado em 27-06-2011.
29. European Medicines Agency: clopidogrel mylan, publicado a 14/10/2009.
30. INFARMED: Resumo das Caraterísticas do Medicamento - Nexium, 20 mg. Aprovado em 13-08-2014.
31. INFARMED: Resumo das Caraterísticas do Medicamento - Kompensan 340 mg comprimidos para chupar. Aprovado 25-03-2014.
32. INFARMED: Resumo das Caraterísticas do Medicamento - Enalapril ratiopharm 20 mg. Aprovado em 15-01-2016.
33. Portaria n.º 1429/2007, de 2 de novembro - Define os serviços farmacêuticos que podem ser prestados pelas farmácias.
34. Lei n.º 131/2015, de 4 de setembro - Estatutos da Ordem dos Farmacêuticos.
35. Instituto Nacional de Cardiologia Preventiva - Hipertensão Arterial. Disponível em http://www.incp.pt. [acedido a 18 de julho de 2016].
36. Fundação Portuguesa de Cardiologia - Tensão e Hipertensão arterial. Disponível em http://www.fpcardiologia.pt. [acedido a 18 de julho de 2016].
37. Direção Geral de Saúde - Estudo da Prevalência da Diabetes em Portugal. Disponível em http://www.dgs.pt. [acedido a 23 de julho de 2016].
38. Norma DGS n.º 33/2011, de 30 de setembro - Prescrição e Determinação da Hemoglobina Glicada A1c, atualizada a 6 de dezembro de 2012.
39. Norma DGS n.º 2/2001, de 14 de janeiro - Diagnóstico e Classificação da Diabetes Mellitus.
40. Norma DGS 66/2011, de 30 de dezembro - Prescrição de Exames Laboratoriais para Avaliação de Dislipidemias no Adulto, atualizada a 26 de fevereiro de 2015.
41. Ordem dos Farmacêuticos (1998). Código Deontológico da Ordem dos Farmacêuticos. 42. Paixão E., Branco M., Contreiras T: Uma observação sobre a prevalência do sono em
Portugal Continental. Onsa 2006; 6-8.
43. Charles L. Nunn, David R. Samson, Andrew D. Krystal: Shining evolutionary light on human sleep and sleep disorders. Evoluation, Medicine & Public Health 2016; 227-231. 44. Ancoli-Israel S, Roth T: Characteristics of insomnia in the United States: results of the
1991 National Sleep Foundation Survey. I. Sleep 1999; 47-53.
45. Ohayon MM: Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002; 97–111.
46. Maurice M. Ohayona, Teresa Paiva: Global sleep dissatisfaction for the assessment of insomnia severity in the general population of Portugal. 1-3.
47. Ohayon MM, Paiva T: Global sleep dissatisfaction for the assessment of insomnia severity in the general population of Portugal. Sleep Medicine 2005; 435-441.
48. Rechtschaffen A, Bergmann BM: Sleep deprivation in the rat: na update of the 1989 paper. Sleep. 2002; 18-24.
49. Aserinsky E, Kleitman N: Regularly occurring periods of eye motility,and concomitant phenomena during sleep. J Neuropsychiatry Clin Neurosci. 2003.
51. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al: The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad USA. 1998.
52. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein- coupled receptors that regulate feeding behavior. Cell. 1998,92(5):573-85. Comment in: Cell. 1998.
53. Mignot E, Taheri S, Nishino S: Sleeping with the hypothalamus: emerging therapeutic targes for sleep disorders. Nat Neurosci. 2002.
54. Alóe F, Azevedo A, Hasan R: Sleep-wake cycle mechanisms. Rev Bras Psiquiatr 2005; 33- 40.
55. Chokroverty S: Overview of sleep & sleep disorders. Indian J Med Res 2010; 126-140. 56. Fernandes R: O sono normal. Simpósio: Distúrbios Respiratórios do sono 2006; 157 –
168.
57. Dement W, Kleitman N: Cyclic variations in EEG during sleep and their relation to eye movements, body motility, and dreaming. Electroencephalogr Clin Neurophysiol 1957; 9: 673-690.
58. Clemente V: Como tratar os doentes com insónia crónica? O contributo da Psicologia Clínica. Rev Port Clin Geral 2006; 635-644.
59. Forattini O: Challenges & Innovation in Health. IPLeiria International Health Congress 2014; 263.
60. Ramakrishnan K, Scheid DC: Treatment Options for Insomnia. Am Fam Physician 2007; 517-526, 527-528.
61. Leopando ZE, Dela Cruz A, Limoso DD, Marcos JA, Alba ME: Clinical practice guidelines on the diagnosis and management of insomnia in family practice: part 1. Asia Pacific Fam Med 2002;1:94-100.
62. Reeder CE, Franklin M, Bramley TJ: Current landscape of insomnia in managed care. Am J Manag Care. 2007; 13:112-116.
63. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M: Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008;4:487-504.
64. Kay-Stacey M, Attarian H: Advances in the management of chronic insomnia. BMJ 2016. 65. Kierlin L: Sleeping without a pill: nonpharmacologic treatments for insomnia. J Psychiatr
66. Harsora P, Kessmann J: Nonpharmacologic Management of Chronic Insomnia. Am Fam Physician 2009;79:125-130.
67. Culpepper L: Secondary insomnia in the primary care setting: review of diagnosis, treatment, and management. Curr Med Res Opin. 2006: 1257-1268.
68. Cavadas L, Ribeiro L: Abordagem da insónia secundária do adulto nos cuidados de saúde primários. Acta Med Port 2011: 135-144.
69. UpToDate: Clinical features and diagnosis of insomnia. Acessível em:http://www.uptodate.com/contents/clinical-features-and-diagnosis-of-insomnia. [acedido a 15 de agosto de 2016].
70. The insomnia guideline working group. Adult Conditioned Insomnia: Diagnosis to Management.Toward Optimized Practice 2008;1-8.
71. Moutinho dos Santos J: Abordagem do doente com patologia do sono. Rev Port Clin Geral 2006;599-610.
72. Stepanski EJ, Wyatt JK: Use of sleep hygiene in the treatment of insomnia. Sleep Medicine Reviews 2003; 7: 215-225.
73. Norma DGS n.º 55/2011, de 27 de dezembro - Tratamento Sintomático da Ansiedade e Insónia com Benzodiazepinas e Fármacos Análogos, atualizada a 21 de janeiro de 2015. 74. Jessica C. Levenson , PhD ; Daniel B. Kay , PhD ; and Daniel J. Buysse , MD: Th e
Pathophysiology of Insomnia. Chest 2015; 147( 4 ): 1179 – 1192.
75. Leopando ZE, Dela Cruz A, Limoso DD, Marcos JA, Alba ME: Clinical practice guidelines on the diagnosis and management of insomnia in family practice: part 2. Asia Pacific Fam Med 2003;2:45-50.
76. Serra J: Terapêutica farmacológica da insónia. Rev Port Clin Geral 2006;22:625-632. 77. Weilburg J: Approach to the patient with insomnia. Em: Primary care medicine: office
evaluation and Management of the adult patient. Allan H. Goroll, Albert G. Mulley Jr. 6th ed. Philadelphia 2009;1483-90.
78. Bruls E, Crasson M, Van-Reeth O, Legros JJ (2000). Melatonin. II. Physiological and therapeutic effects. Revue medicale de Liege; 55: 862-870.
79. Circadin® – Resumo das Características do Medicamento (2010).
80. Buscemi N, Vandermmer B, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders a meta-analysis. Journal of General Internal Medicine 2005; 20: 1151-1158.
81. Lieberman JA 3rd, Neubauer DN: Understanding insomnia: Diagnosis and management of a common sleep disorder. J Fam Pract. 2007;56(10A):35A-49ª.
82. Agência Europeia do Medicamento (2008). Questions and answers on the withdrawal of the marketing application for Diractin.
83. Medina AB, Lechuga DA, Escandón OS, Moctezuma JV: Update of sleep alterations in depression. Sleep Sci. 2014;7(3):165-9.
84. World Health Organization, Cardiovascular Diseases, disponível em http://www.who.int/cardiovascular_diseases/en/ [acedido a 13 de agosto de 2016]. 85. European Guidelines on cardiovascular disease prevention in clinical practice. European
Heart Journal 2012; 4-56.
86. World Health Organization. Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases. 2002. Report No. 916.
87. Last JM, ed: A Dictionary of Epidemiology. 4th ed. New York: Oxford University Press; 2001.
88. Rose G: Sick individuals and sick populations. Int J Epidemiol 1985; 14:32–38.
89. Manuel DG, Lim J, Tanuseputro P, Anderson GM, Alter DA, Laupacis A, Mustard CA: Revisiting Rose: strategies for reducing coronary heart disease. BMJ 2006; 332:659– 662.
90. Forsen T, Eriksson JG, Tuomilehto J, Osmond C, Barker DJ: Growth in utero and during childhood among women who develop coronary heart disease: longitudinal study. BMJ 1999; 319:1403–1407.
91. Painter RC, de Rooij SR, Bossuyt PM, Simmers TA, Osmond C, Barker DJ, Bleker OP, Roseboom TJ: Early onset of coronary artery disease after prenatal exposure to the Dutch famine. Am J Clin Nutr 2006; 84:322–327; 466–327.
92. Vos LE, Oren A, Uiterwaal C, Gorissen WH, Grobbee DE, Bots M: Adolescent blood pressure and blood pressure tracking into young adulthood are related to subclinical atherosclerosis: the Atherosclerosis Risk in Young Adults (ARYA) study. Am J Hypertens 2003; 16:549–555.
93. Marmot M: Sustainable development and the social gradient in coronary heart disease. Eur Heart J 2001; 22:740–750.
94. Williams RR, Hunt SC, Heiss G, Province MA, Bensen JT, Higgins M, Chamberlain RM, Ware J, Hopkins PN: Usefulness of cardiovascular family history data for population- based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol 2001;87:129–135.
95. Paynter NP, Chasman DI, Pare G, Buring JE, Cook NR, Miletich JP, Ridker PM: Association between a literature-based genetic risk score and cardiovascular events in women. JAMA 2010;303:631 – 637.
96. Huijgen R, Kindt I, Verhoeven SB, Sijbrands EJ, Vissers MN, Kastelein JJ, Hutten BA: Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010; 5:9220.
97. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P,Wilhelmsen L, Graham IM: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987– 1003.
98. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risc factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999; 99:1165–1172.
99. Schisterman EF, Whitcomb BW: Coronary age as a risk factor in the modified Framingham risk score. BMC Med Imaging 2004; 4:1.
100. European Heart Network. European Cardiovascular Disease Statistics. 2008 edition. 101. Lawlor DA, Ebrahim S, Davey Smith G. Sex matters: secular, geographical trends in sex
differences in coronary heart disease mortality. BMJ 2001; 323:541–545.
102. Woodward M, Brindle P, Tunstall-Pedoe H: Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007; 93:172–176.
103. Stringhini S, Sabia S, Shipley M, Brunner E, Nabi H, Kivimaki M, Singh-Manoux A: Association of socioeconomic position with health behaviors and mortality. JAMA 2010; 303:1159–1166.
104. Albert MA, Glynn RJ, Buring J, Ridker PM: Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events. Circulation 2006; 114:2619–2626.
105. Huisman M, Kunst AE, Mackenbach JP: Inequalities in the prevalence of smoking in the European Union: comparing education and income. Prev Med 2005;40: 756–764. 106. Linden W, Phillips MJ, Leclerc J: Psychological treatment of cardiac patients: a meta-
analysis. Eur Heart J 2007; 28:2972–2984.
107. Edwards R: The problem of tobacco smoking. BMJ 2004; 328:217–219.
108. Raupach T, Schafer K, Konstantinides S, Andreas S: Secondhand smoke as na acute threat for the cardiovascular system: a change in paradigm. Eur Heart J 2006; 27:386– 392.
109. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J: Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998; 316:1043– 1047.
110. Mucha L, Stephenson J, Morandi N, Dirani R: Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. Gend Med 2006;3: 279–291. 111. SIGN (Scottish Intercollegiate Guidelines Network). Risk Estimation and the Prevention
of Cardiovascular Disease. A National Clinical Guideline. 2007. Report No. 97.
112. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen L, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgozoglu L, Wiklund O, Zampelas A: European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 Suppl 2:S1–113.
113. Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S: Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121:750–758.
114. Keys A: Effects of different dietary fats on plasma-lipid levels. Lancet 1965;1: 318–319. 115. He FJ, MacGregor GA: Effect of modest salt reduction on blood pressure: a meta- analysis of randomized trials. Implications for public health. J Hum Hypertens 2002; 16:761–770.
116. Weickert MO, Pfeiffer AF: Metabolic effects of dietary fiber consumption and prevention of diabetes. J Nutr 2008; 138:439–442.
117. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N: A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336:1117–1124.
118. He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR, Greenland P: Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 2004; 109:2705–2711.
119. Corrao G, Bagnardi V, Zambon A, La Vecchia C: A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004;38:613–619.
120. Talbot LA, Morrell CH, Fleg JL, Metter EJ: Changes in leisure time physical activity and risk of all-cause mortality in men and women: the Baltimore Longitudinal Study of Aging. Prev Med 2007;45:169–176.
121. Richardson CR, Kriska AM, Lantz PM, Hayward RA: Physical activity and mortality across cardiovascular disease risk groups. Med Sci Sports Exerc 2004;36: 1923–1929. 122. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, Skidmore B, Stone JA,
Thompson DR, Oldridge N: Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004;116:682–692.
123. Warren TY, Barry V, Hooker SP, Sui X, Church TS, Blair SN: Sedentary behaviors increase risk of cardiovascular disease mortality in men. Med Sci Sports Exerc 2010;42:879–885.
124. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J Qizilbash N, Collins R, Peto R: Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083–1096.
125. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH: Obesity, cardiovascular disease: pathophysiology, evaluation, effect of weight loss: na update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898 – 918.
126. Haslam DW, James WP: Obesity. Lancet 2005;366:1197 – 1209.
127. Nordhamn K, Sodergren E, Olsson E, Karlstrom B, Vessby B, Berglund L: Reliability of anthropometric measurements in overweight and lean subjects: consequences for correlations between anthropometric and other variables. Int J Obes Relat Metab Disord 2000;24:652 – 657.
128. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765 – 774.
129. He FJ, Nowson CA, MacGregor GA: Fruit and vegetable consumption and stroke: meta- analysis of cohort studies. Lancet 2006;367:320 – 326.
130. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755 – 1762. 131. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna
A, LaRosa J, Grundy S, Waters D: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29:1220–1226.
132. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560–2572.
133. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–713.
134. Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994;308:81–106. 135. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J,
Wentworth D: Serum cholesterol level mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152:1490–1500.
136. Smith GD, Shipley MJ, Marmot MG, Rose G: Plasma cholesterol concentration, mortality. The Whitehall Study. JAMA 2012; 267:70–76.
137. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF: Triglyceride- rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32:1345–1361.
138. Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G, Wautrecht JC, Kornitzer M, Newman AB, Cushman M,
Sutton-Tyrrell K, Lee AJ, Price JF, d’Agostino RB, Murabito JM, Norman PE, Jamrozik K, Curb JD, Masaki KH, Rodriguez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels G, Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi JD, Knottnerus JA, Ogren M, Hedblad B, Witteman JC, Breteler MM, Hunink MG, Hofman A, Criqui MH, Langer RD, Fronek A, Hiatt WR, Hamman R, Resnick HE, Guralnik J. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008; 300:197–208.
139. Streilein JW: The skin-associated lymphoid tissue (SALT): origins and functions. J Invest Dermatol 2014.
140. Krutmann J, Ahrens C, Roza L, Arlett CF: The role of DNA damage and repair in ultraviolet B radiation-induced immunomodulation: relevance for human photocarcinogenesis. Photochem Photobiol 2010;63:394–396.
141. Scharffetter-Kochanek K, Brenneisen P, Wenk J, et al. Photoaging of the skin from phenotype to mechanisms. Exp Gerontol 2000; 35:307–16.
142. Roe DA: Current etiologies and cutaneous signs of vitamin deficiencies. In: Roe DA, ed. Nutrition and the skin. Contemporary issues in clinical nutrition. New York: Alan R Liss Inc, 2009:81–98.